Selected article for: "active replication and virus replication"
Author: Mengist, Hylemariam Mihiretie; Mekonnen, Daniel; Mohammed, Ahmed; Shi, Ronghua; Jin, Tengchuan
Title: Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
  • Cord-id: dqycozpe
  • Document date: 2021_2_1
    • ID: dqycozpe
    Snippet: Effective, safe, and pharmacokinetically suitable drugs are urgently needed to curb the ongoing COVID-19 pandemic. The main protease or 3C-like protease (M(pro) or 3CL(pro)) of SARS-CoV-2 is considered an important target to formulate potent drugs corresponding to its crucial role in virus replication and maturation in addition to its relatively conserved active site. Promising baseline data on the potency and safety of drugs targeting SARS-CoV-2 M(pro) are currently available. However, preclini
    Document: Effective, safe, and pharmacokinetically suitable drugs are urgently needed to curb the ongoing COVID-19 pandemic. The main protease or 3C-like protease (M(pro) or 3CL(pro)) of SARS-CoV-2 is considered an important target to formulate potent drugs corresponding to its crucial role in virus replication and maturation in addition to its relatively conserved active site. Promising baseline data on the potency and safety of drugs targeting SARS-CoV-2 M(pro) are currently available. However, preclinical and clinical data on the pharmacokinetic profiles of these drugs are very limited. This review discusses the potency, safety, and pharmacokinetic profiles of potential inhibitors of SARS-CoV-2 M(pro) and forward directions on the development of future studies focusing on COVID-19 therapeutics.

    Search related documents:
    Co phrase search for related documents
    • absence presence and activity inhibit: 1, 2, 3, 4
    • absence presence and lopinavir ritonavir: 1, 2
    • absence presence and low toxicity: 1, 2
    • active site and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • active site and low cytotoxicity: 1, 2
    • active site and low toxicity: 1, 2
    • activity inhibit and lopinavir ritonavir: 1, 2
    • activity inhibit and low cytotoxicity: 1
    • activity inhibit and low toxicity: 1, 2
    • lopinavir ritonavir and low clearance: 1
    • lopinavir ritonavir and low cytotoxicity: 1
    • lopinavir ritonavir and low toxicity: 1